Literature DB >> 3714615

Parkinsonism induced by a monoamine oxidase inhibitor.

M A Gillman, R Sandyk.   

Abstract

A parkinsonian syndrome developed 5 weeks after administration of phenelzine in a 42 year old woman with major depressive illness. Discontinuation of this agent resulted in gradual disappearance of the extrapyramidal syndrome. Possible underlying mechanisms for this unusual case are discussed.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3714615      PMCID： PMC2418638          DOI： 10.1136/pgmj.62.725.235

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN： 0032-5473            Impact factor:   2.401


  6 in total

1.  The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil.

Authors:  W Birkmayer; P Riederer; M B Youdim; W Linauer
Journal:  J Neural Transm       Date:  1975       Impact factor: 3.575

2.  Biochemical evidence of adrenergic interaction with cholinergic function in the central nervous system of the rat. 1. Effect of norepinephrine.

Authors:  A K Ho; G Singer; S Gershon
Journal:  Psychopharmacologia       Date:  1971

3.  Serotonin--dopamine interactions in the nigrostriatal system.

Authors:  P C Waldmeier; A A Delini-Stula
Journal:  Eur J Pharmacol       Date:  1979-05-15       Impact factor: 4.432

4.  Parkinsonian side effects induced by a monoamine oxidase inhibitor.

Authors:  J P Teusink; G S Alexopoulos; C A Shamoian
Journal:  Am J Psychiatry       Date:  1984-01       Impact factor: 18.112

5.  Clinical pharmacology of phenelzine.

Authors:  D S Robinson; A Nies; C L Ravaris; J O Ives; D Bartlett
Journal:  Arch Gen Psychiatry       Date:  1978-05

6.  Deprenyl in Parkinson's disease.

Authors:  A J Lees; K M Shaw; L J Kohout; G M Stern; J D Elsworth; M Sandler; M B Youdim
Journal:  Lancet       Date:  1977-10-15       Impact factor: 79.321
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.